Abbisko Cayman Limited (HKG:2256)
Hong Kong · Delayed Price · Currency is HKD 9.03
+0.05 (0.56%)
Jun 18, 2026, 4:08 PM HKT
Abbisko Cayman Revenue
In the year 2025, Abbisko Cayman had annual revenue of 612.12M CNY with 21.45% growth.
Revenue
612.12M CNY
Revenue Growth
+21.45%
P/S Ratio
9.45
Revenue / Employee
2.22M CNY
Employees
276
Market Cap
6.43B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 612.12M | 108.13M | 21.45% |
| Dec 31, 2024 | 503.99M | 484.93M | 2,544.24% |
| Dec 31, 2023 | 19.06M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 22.68M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Shanghai Haohai Biological Technology | 2.73B |
| Everest Medicines | 1.90B |
| HBM Holdings | 1.23B |
| Lepu Biopharma | 1.04B |
| Alphamab Oncology | 630.11M |
| CStone Pharmaceuticals | 299.99M |
| Suzhou Ribo Life Science | 165.26M |